American Association of Feline Practitioners

Veterinary professionals passionate about the care of cats

Update on Feline Viral Respiratory Disease

Update on Feline Viral Respiratory Disease with Emphasis on Feline Calicivirus


 You must login to view this webinar.
 

Access Webinar

If you are not an AAFP member,
create an account or login to the 
Non-Member AAFP Portal

In this webinar, Dr. Michael Lappin will present updated information on viral causes of respiratory diseases in cats with an emphasis on caliciviruses and feline herpesvirus 1.

This webinar's objectives include:

  • Reviewing the causes of viral URI in cats.
  • Emphasizing the importance of caliciviruses.
  • Emphasizing the difficulties in determining the cause
    of URI in cats.
  • Emphasizing the importance of vaccination in the management of viral URI in cats.
  • Updating the optimal treatments for viral URI.

Speaker Bio

Michael Lappin, DVM, PhD, DACVIM

Dr. Lappin is a board-certified ACVIM diplomate that has been studying infectious diseases of cats for many years. Dr. Lappin has a PhD in parasitology and his Center for Companion Animal Studies has studied feline respiratory viruses for many years emphasizing treatment and prevention. Dr. Lappin is a member of the AAFP Vaccine Guidelines panel.


RACE Credits 

This program 249-25125 is approved by the AAVSB RACE to offer a total of 1.00 CE Credits (1.00 max) being available to any one veterinarian: and/or 1.00 Veterinary Technician CE Credits (1.00 max). This RACE approval is for the subject matter categorie(s) of: Scientific using the delivery method(s) of: Non-Interactive-Distance. This approval is valid in jurisdictions which recognize AAVSB RACE; however, participants are responsible for ascertaining each board's CE requirements.


Disclosure Statement

This webinar is sponsored by Boehringer Ingelheim. Speakers are expected to disclose conflict of interests whenever a conflict arises relating to the topics of this educational webinar.

Dr. Lappin performs research with several companies that produce FeLV and FIV vaccines or tests and will only be presenting results of peer-reviewed publications.